|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q63468404
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010848.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q63468404
|
|
035
|
|
|
‡a
(OCoLC)Q63468404
|
|
100
|
0 |
|
‡a
Edward Neely Atkinson
‡9
en
‡9
nl
‡9
ast
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
670
|
|
|
‡a
Author's A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
|
|
670
|
|
|
‡a
Author's Combined reflectance and fluorescence spectroscopy for in vivo detection of cervical pre-cancer
|
|
670
|
|
|
‡a
Author's Development of a multivariate statistical algorithm to analyze human cervical tissue fluorescence spectra acquired in vivo
|
|
670
|
|
|
‡a
Author's Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
|
|
670
|
|
|
‡a
Author's Intrinsic resistance to anticancer agents in the murine pancreatic adenocarcinoma PANC02.
|
|
670
|
|
|
‡a
Author's Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram P values for multiple comparisons.
|
|
670
|
|
|
‡a
Author's Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues
|
|
670
|
|
|
‡a
Author's Metastatic potential of human colorectal carcinomas implanted into nude mice: prediction of clinical outcome in patients operated upon for cure
|
|
670
|
|
|
‡a
Author's MRI-guided vacuum-assisted breast biopsy performed at 3 T with a 9-gauge needle: preliminary experience
|
|
670
|
|
|
‡a
Author's Multicenter clinical trials of in vivo fluorescence: are the measurements equivalent?
|
|
670
|
|
|
‡a
Author's Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells
|
|
670
|
|
|
‡a
Author's Optical technologies and molecular imaging for cervical neoplasia: a program project update
|
|
670
|
|
|
‡a
Author's Parameters of small bowel dysfunction in cervical cancer patients undergoing radiotherapy
|
|
670
|
|
|
‡a
Author's Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
|
|
670
|
|
|
‡a
Author's Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
|
|
670
|
|
|
‡a
Author's Phase 2 trial of mifepristone
|
|
670
|
|
|
‡a
Author's Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma
|
|
670
|
|
|
‡a
Author's Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia
|
|
670
|
|
|
‡a
Author's Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix
|
|
670
|
|
|
‡a
Author's Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells
|
|
670
|
|
|
‡a
Author's Prognostic factors for patients undergoing simple hysterectomy in the presence of invasive cancer of the cervix
|
|
670
|
|
|
‡a
Author's Reflectance spectroscopy for in vivo detection of cervical precancer
|
|
670
|
|
|
‡a
Author's Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer
|
|
670
|
|
|
‡a
Author's Second malignancies after chemotherapy and radiotherapy for Hodgkin disease
|
|
670
|
|
|
‡a
Author's Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis
|
|
670
|
|
|
‡a
Author's Survival following locoregional recurrence after breast conservation therapy for cancer
|
|
670
|
|
|
‡a
Author's Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo
|
|
670
|
|
|
‡a
Author's Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells
|
|
670
|
|
|
‡a
Author's The clinical effectiveness of fluorescence and reflectance spectroscopy for the in vivo diagnosis of cervical neoplasia: an analysis by phase of trial design
|
|
670
|
|
|
‡a
Author's The correlation of two argyrophilic nucleolar organizer region counting methods with bromodeoxyuridine-labeling index: a study of metastatic tumors of the brain
|
|
670
|
|
|
‡a
Author's The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
|
|
670
|
|
|
‡a
Author's Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy
|
|
670
|
|
|
‡a
Author's Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma
|
|
670
|
|
|
‡a
Author's Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
|
|
670
|
|
|
‡a
Author's Virus-augmented delayed hypersensitivity skin tests in gynecological malignancies
|
|
919
|
|
|
‡a
docetaxelforpatientswithpaclitaxelresistantmulleriancarcinoma
‡A
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
‡9
1
|
|
919
|
|
|
‡a
developmentofamultivariatestatisticalalgorithmtoanalyzehumancervicaltissuefluorescencespectraacquiredinvivo
‡A
Development of a multivariate statistical algorithm to analyze human cervical tissue fluorescence spectra acquired in vivo
‡9
1
|
|
919
|
|
|
‡a
combinedreflectanceandfluorescencespectroscopyforinvivodetectionofcervicalprecancer
‡A
Combined reflectance and fluorescence spectroscopy for in vivo detection of cervical pre-cancer
‡9
1
|
|
919
|
|
|
‡a
phase2trialoforalcapecitabineinpatientswithplatinumandtaxanerefractoryovarianfallopiantubeorperitonealcancer
‡A
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
‡9
1
|
|
919
|
|
|
‡a
virusaugmenteddelayedhypersensitivityskintestsingynecologicalmalignancies
‡A
Virus-augmented delayed hypersensitivity skin tests in gynecological malignancies
‡9
1
|
|
919
|
|
|
‡a
urinarymesothelinprovidesgreatersensitivityforearlystageovariancancerthanserummesothelinurinaryhcgfreebetasubunitandurinaryhcgbetacorefragment
‡A
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
‡9
1
|
|
919
|
|
|
‡a
ultrastagingimprovesdetectionofmetastasesinsentinellymphnodesofuterinecervixsquamouscellcarcinoma
‡A
Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma
‡9
1
|
|
919
|
|
|
‡a
tumorsuppressor101f6andascorbatesynergisticallyandselectivelyinhibitnonsmallcelllungcancergrowthbycaspaseindependentapoptosisandautophagy
‡A
Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy
‡9
1
|
|
919
|
|
|
‡a
humanlipidphosphatephosphatase3decreasesthegrowthsurvivalandtumorigenesisofovariancancercellsvalidationofthelysophosphatidicacidsignalingcascadeasatargetfortherapyinovariancancer
‡A
The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
‡9
1
|
|
919
|
|
|
‡a
correlationof2argyrophilicnucleolarorganizerregioncountingmethodswithbromodeoxyuridinelabelingindexastudyofmetastatictumorsofthebrain
‡A
The correlation of two argyrophilic nucleolar organizer region counting methods with bromodeoxyuridine-labeling index: a study of metastatic tumors of the brain
‡9
1
|
|
919
|
|
|
‡a
clinicaleffectivenessoffluorescenceandreflectancespectroscopyfortheinvivodiagnosisofcervicalneoplasiaananalysisbyphaseoftrialdesign
‡A
The clinical effectiveness of fluorescence and reflectance spectroscopy for the in vivo diagnosis of cervical neoplasia: an analysis by phase of trial design
‡9
1
|
|
919
|
|
|
‡a
synergistictumorsuppressionbycoexpressionoffhitandp53coincideswithfhitmediatedmdm2inactivationandp53stabilizationinhumannonsmallcelllungcancercells
‡A
Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells
‡9
1
|
|
919
|
|
|
‡a
synergisticinhibitionofhumanlungcancercellgrowthbyadenovirusmediatedwildtypep53genetransferincombinationwithdocetaxelandradiationtherapeuticsinvitroandinvivo
‡A
Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo
‡9
1
|
|
919
|
|
|
‡a
survivalfollowinglocoregionalrecurrenceafterbreastconservationtherapyforcancer
‡A
Survival following locoregional recurrence after breast conservation therapy for cancer
‡9
1
|
|
919
|
|
|
‡a
selectionofpotentialmarkersforepithelialovariancancerwithgeneexpressionarraysandrecursivedescentpartitionanalysis
‡A
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis
‡9
1
|
|
919
|
|
|
‡a
2malignanciesafterchemotherapyandradiotherapyforhodgkindisease
‡A
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease
‡9
1
|
|
919
|
|
|
‡a
roleofdecreasedlevelsoflipidphosphatephosphatase1inaccumulationoflysophosphatidicacidinovariancancer
‡A
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer
‡9
1
|
|
919
|
|
|
‡a
reflectancespectroscopyforinvivodetectionofcervicalprecancer
‡A
Reflectance spectroscopy for in vivo detection of cervical precancer
‡9
1
|
|
919
|
|
|
‡a
prognosticfactorsforpatientsundergoingsimplehysterectomyinthepresenceofinvasivecancerofthecervix
‡A
Prognostic factors for patients undergoing simple hysterectomy in the presence of invasive cancer of the cervix
‡9
1
|
|
919
|
|
|
‡a
plasmacytoiddendriticcellspromoteimmunosuppressioninovariancancerviaicoscostimulationoffoxp3+tregulatorycells
‡A
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells
‡9
1
|
|
919
|
|
|
‡a
phase2trialofcapecitabineinrecurrentsquamouscellcarcinomaofthecervix
‡A
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix
‡9
1
|
|
919
|
|
|
‡a
phase2clinicaltrialofn4hydroxyphenylretinamideandtamoxifenadministrationbeforedefinitivesurgeryforbreastneoplasia
‡A
Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia
‡9
1
|
|
919
|
|
|
‡a
phase2trialofmifepristoneru486inadvancedorrecurrentendometrioidadenocarcinomaorlowgradeendometrialstromalsarcoma
‡A
Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma
‡9
1
|
|
919
|
|
|
‡a
phase2trialofmifepristone
‡A
Phase 2 trial of mifepristone
‡9
1
|
|
919
|
|
|
‡a
perifosineplusdocetaxelinpatientswithplatinumandtaxaneresistantorrefractoryhighgradeepithelialovariancancer
‡A
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
‡9
1
|
|
919
|
|
|
‡a
patternsofgeneexpressionindifferenthistotypesofepithelialovariancancercorrelatewiththoseinnormalfallopiantubeendometriumandcolon
‡A
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
‡9
1
|
|
919
|
|
|
‡a
parametersofsmallboweldysfunctionincervicalcancerpatientsundergoingradiotherapy
‡A
Parameters of small bowel dysfunction in cervical cancer patients undergoing radiotherapy
‡9
1
|
|
919
|
|
|
‡a
opticaltechnologiesandmolecularimagingforcervicalneoplasiaaprogramprojectupdate
‡A
Optical technologies and molecular imaging for cervical neoplasia: a program project update
‡9
1
|
|
919
|
|
|
‡a
myristoylationofthefus1proteinisrequiredfortumorsuppressioninhumanlungcancercells
‡A
Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells
‡9
1
|
|
919
|
|
|
‡a
multicenterclinicaltrialsofinvivofluorescencearethemeasurementsequivalent
‡A
Multicenter clinical trials of in vivo fluorescence: are the measurements equivalent?
‡9
1
|
|
919
|
|
|
‡a
mriguidedvacuumassistedbreastbiopsyperformedat3twitha9gaugeneedlepreliminaryexperience
‡A
MRI-guided vacuum-assisted breast biopsy performed at 3 T with a 9-gauge needle: preliminary experience
‡9
1
|
|
919
|
|
|
‡a
metastaticpotentialofhumancolorectalcarcinomasimplantedintonudemicepredictionofclinicaloutcomeinpatientsoperateduponforcure
‡A
Metastatic potential of human colorectal carcinomas implanted into nude mice: prediction of clinical outcome in patients operated upon for cure
‡9
1
|
|
919
|
|
|
‡a
kappastatisticstomeasureinterraterandintrarateragreementfor1790cervicalbiopsyspecimensamong12pathologistsqualitativehistopathologicanalysisandmethodologicissues
‡A
Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues
‡9
1
|
|
919
|
|
|
‡a
isasciticfluidinterleukin12anindependentprognosticfactorinovariancancerthenecessityofcorrectionmilligrampvaluesformultiplecomparisons
‡A
Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram P values for multiple comparisons.
‡9
1
|
|
919
|
|
|
‡a
intrinsicresistancetoanticanceragentsinthemurinepancreaticadenocarcinomapanc02
‡A
Intrinsic resistance to anticancer agents in the murine pancreatic adenocarcinoma PANC02.
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
NLA|000035447976
|
|
996
|
|
|
‡2
N6I|vtls000000739
|
|
996
|
|
|
‡2
LC|n 84805038
|
|
996
|
|
|
‡2
NII|DA0291276X
|
|
996
|
|
|
‡2
LC|n 2017186695
|
|
996
|
|
|
‡2
J9U|987007423424005171
|
|
996
|
|
|
‡2
N6I|vtls000022864
|
|
996
|
|
|
‡2
RERO|A013394169
|
|
996
|
|
|
‡2
NTA|15303534X
|
|
996
|
|
|
‡2
SUDOC|073300667
|
|
996
|
|
|
‡2
LC|no2014162197
|
|
996
|
|
|
‡2
BNF|12477059
|
|
996
|
|
|
‡2
DNB|122357655
|
|
996
|
|
|
‡2
ISNI|0000000083680881
|
|
996
|
|
|
‡2
DNB|138884021
|
|
996
|
|
|
‡2
LC|n 85809272
|
|
996
|
|
|
‡2
LC|n 90676894
|
|
996
|
|
|
‡2
NTA|068375387
|
|
996
|
|
|
‡2
SUDOC|150704399
|
|
996
|
|
|
‡2
NII|DA06964390
|
|
996
|
|
|
‡2
N6I|vtls000028963
|
|
996
|
|
|
‡2
DNB|1272888150
|
|
996
|
|
|
‡2
NDL|00768865
|
|
996
|
|
|
‡2
J9U|987007281062205171
|
|
996
|
|
|
‡2
NII|DA1270272X
|
|
996
|
|
|
‡2
NKC|xx0240367
|
|
996
|
|
|
‡2
LC|no2020037382
|
|
996
|
|
|
‡2
N6I|vtls000284259
|
|
996
|
|
|
‡2
ISNI|0000000374247666
|
|
996
|
|
|
‡2
SUDOC|192963112
|
|
996
|
|
|
‡2
NUKAT|n 2015144590
|
|
996
|
|
|
‡2
SUDOC|243809085
|
|
996
|
|
|
‡2
BIBSYS|90357227
|
|
996
|
|
|
‡2
LC|n 88127814
|
|
996
|
|
|
‡2
NTA|067625746
|
|
996
|
|
|
‡2
CAOONL|ncf10099879
|
|
996
|
|
|
‡2
ISNI|0000000076561999
|
|
996
|
|
|
‡2
RERO|A002949746
|
|
996
|
|
|
‡2
RERO|A002949745
|
|
996
|
|
|
‡2
LIH|LNB:K_p__o_;=B6
|
|
996
|
|
|
‡2
RERO|A022937730
|
|
996
|
|
|
‡2
BNC|981058614763606706
|
|
996
|
|
|
‡2
RERO|A005501385
|
|
996
|
|
|
‡2
N6I|vtls000000605
|
|
996
|
|
|
‡2
NLA|000036000142
|
|
996
|
|
|
‡2
LC|n 86144604
|
|
996
|
|
|
‡2
BIBSYS|14017586
|
|
996
|
|
|
‡2
BNF|10492938
|
|
996
|
|
|
‡2
LC|no2020142597
|
|
996
|
|
|
‡2
NLA|000036024664
|
|
996
|
|
|
‡2
CAOONL|ncf11597606
|
|
996
|
|
|
‡2
ISNI|000000004263765X
|
|
996
|
|
|
‡2
NLA|000049785062
|
|
996
|
|
|
‡2
DNB|116375590
|
|
996
|
|
|
‡2
LC|n 85173914
|
|
996
|
|
|
‡2
LC|nb2008017564
|
|
996
|
|
|
‡2
ISNI|0000000082166928
|
|
996
|
|
|
‡2
NDL|00771374
|
|
996
|
|
|
‡2
ISNI|0000000066885412
|
|
996
|
|
|
‡2
LC|nr 90021031
|
|
996
|
|
|
‡2
NUKAT|n 2015002421
|
|
996
|
|
|
‡2
NTA|15965405X
|
|
996
|
|
|
‡2
NLA|000058799869
|
|
996
|
|
|
‡2
NLA|000058649019
|
|
996
|
|
|
‡2
CAOONL|ncf10031553
|
|
996
|
|
|
‡2
ISNI|0000000070036915
|
|
996
|
|
|
‡2
N6I|vtls000039001
|
|
996
|
|
|
‡2
J9U|987007438071405171
|
|
996
|
|
|
‡2
NLA|000058652594
|
|
996
|
|
|
‡2
SUDOC|227241819
|
|
996
|
|
|
‡2
N6I|vtls001342550
|
|
996
|
|
|
‡2
N6I|vtls000340821
|
|
996
|
|
|
‡2
CAOONL|ncf10644708
|
|
996
|
|
|
‡2
ISNI|0000000080923657
|
|
996
|
|
|
‡2
PTBNP|1765262
|
|
996
|
|
|
‡2
NKC|xx0268001
|
|
996
|
|
|
‡2
DNB|101966830
|
|
996
|
|
|
‡2
LC|no 90005318
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
